A phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of OPC-131066 Administered in a Randomized, Parallel-group, Placebo-controlled, Double-blind Fashion and Evaluating the Food Effect on the Safety and Pharmacokinetics of OPC-131066 Administered in an Open-label, Crossover Fashion to Healthy Adult Male Subjects
Latest Information Update: 07 Jan 2022
At a glance
- Drugs OPC-131066 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
- 20 Dec 2021 New trial record